HMGCS2 Downregulation Drives Fibroblast Activation in Lung Fibrosis

Study Background and Research Question

Idiopathic pulmonary fibrosis (IPF) is a progressive and ultimately fatal interstitial lung disease, marked by fibrotic remodeling, extracellular matrix deposition, and loss of normal alveolar architecture. Despite the availability of two FDA-approved antifibrotic drugs, median survival remains only 3–5 years following diagnosis, and the disease burden continues to rise globally according to recent epidemiological data from the Asia-Pacific region and the United States (Yang et al., 2024). One increasingly recognized feature of IPF is metabolic dysregulation, especially alterations in lipid metabolism detectable in patient serum and bronchoalveolar lavage fluid. However, the precise cellular source of these lipid species and their functional roles in fibrosis progression have remained poorly understood. Yang et al. (2024) set out to determine the origin and pathogenic contribution of lipid metabolic alterations, focusing on the role of 3-hydroxy-3-methylglutaryl-CoA synthase 2 (HMGCS2) in type II alveolar epithelial cells (AECIIs) and their downstream effects on fibroblast activation.

Key Innovation from the Reference Study

The central innovation in Yang et al.'s work is the identification of injured AECIIs as the primary source of lysophospholipid accumulation—particularly lysophosphatidylcholines (LysoPCs, including 1-myristoylglycerophosphocholine/14:0 Lyso-PC)—in fibrotic lung tissue. The study demonstrates that downregulation of HMGCS2 in these cells leads to dysregulated lipid metabolism, resulting in increased release of LysoPCs capable of activating lung fibroblasts. This mechanistic axis represents a novel etiological pathway in IPF, linking epithelial metabolic reprogramming directly to mesenchymal activation and fibrosis progression.

Methods and Experimental Design Insights

Yang et al. employed a multi-tiered experimental strategy integrating in vivo, in vitro, and omics approaches:

• Lung injury modeling: Mice were challenged with bleomycin to induce pulmonary fibrosis; human AECIIs were similarly stimulated in vitro.
• Lipid accumulation detection: Oil-red O histology and immunofluorescence were used to visualize lipid deposits in lung sections and cultured cells.
• Lipidomics: Untargeted mass spectrometry-based lipidomics profiled the spectrum of lipid species accumulating in AECIIs post-injury.
• Functional assays: Exogenous LysoPC and specifically 1-myristoylglycerophosphocholine were applied to human lung fibroblasts and fibrotic mice to assess their capacity to drive fibroblast activation and fibrotic remodeling.
• Gene expression and mechanistic interrogation: Microarray and single-cell RNA-seq datasets were mined to identify differentially expressed lipid metabolism genes. Functional rescue experiments involved ectopic expression of HMGCS2 in AECIIs using an adeno-associated viral (AAV) vector system.
• Protein and pathway analysis: Western blotting, co-immunoprecipitation, site-directed mutagenesis, and flow cytometry elucidated the downstream molecular interactions involving HMGCS2, PPARα, and key fatty acid oxidation enzymes (CPT1A, CPT2).

Protocol Parameters

• Bleomycin-induced injury: Administered intratracheally in mice to induce AECII injury and model pulmonary fibrosis.
• Lipid detection: Oil-red O staining of frozen lung sections and immunofluorescence for cell-type identification.
• LysoPC treatment: LysoPC (including 1-myristoylglycerophosphocholine) applied to cultured human lung fibroblasts in nanomolar to micromolar concentrations; also administered to mice for in vivo fibroblast activation studies.
• AAV-mediated HMGCS2 expression: HBAAV2/6-SFTPC-HMGCS2 delivered intratracheally to overexpress HMGCS2 selectively in AECIIs.
• Omics and gene expression analysis: Untargeted lipidomics, microarray, and single-cell transcriptomics guided candidate selection and validation.

Core Findings and Why They Matter

The study provides several lines of evidence supporting a direct link between epithelial lipid metabolism and fibroblast-driven fibrosis:

• After bleomycin injury, AECIIs showed marked lipid accumulation, with LysoPC species such as 1-myristoylglycerophosphocholine significantly elevated.
• LysoPCs released from injured AECIIs activated lung fibroblasts in vitro, promoting profibrotic gene expression and phenotypic changes. In vivo, LysoPC administration exacerbated fibrosis in mouse models.
• HMGCS2 expression was specifically decreased in AECIIs during fibrosis. Restoring HMGCS2 via AAV delivery normalized lipid metabolism, reduced LysoPC accumulation, and attenuated fibrosis severity.
• Mechanistically, HMGCS2 interacted with PPARα to enhance expression of CPT1A and CPT2, promoting fatty acid β-oxidation and reducing lipid accumulation.

Collectively, these findings establish that HMGCS2 downregulation in AECIIs is a driver of pathological lipid signaling in IPF, with 1-myristoylglycerophosphocholine acting as a paracrine activator of fibroblasts through lysophospholipid-sensitive receptor pathways. This axis opens new avenues for targeted interventions aimed at restoring epithelial lipid homeostasis.

Comparison with Existing Internal Articles

The present findings are consistent with and extend the insights available in related reviews and mechanistic summaries. The internal article "HMGCS2 Downregulation Alters Lipid Metabolism in Pulmonary Fibrosis" highlights that HMGCS2 loss in AECIIs leads to lysophospholipid accumulation and fibroblast activation. Yang et al.'s reference study provides direct experimental validation of this pathway, including in vivo rescue by HMGCS2 overexpression. Another internal resource, "HMGCS2-Mediated Lipid Metabolism Drives Pulmonary Fibrosis", also reviews the mechanistic link between epithelial lipid metabolism and fibroblast activation, further confirming the central role of the HMGCS2–LysoPC axis in fibrotic remodeling. Together, these resources establish a consensus that targeting lipid metabolic pathways in AECIIs represents a promising therapeutic approach.

Limitations and Transferability

While the study by Yang et al. offers significant mechanistic clarity, there are important considerations for translation and further research:

• Model constraints: The primary experimental platform is the bleomycin-induced mouse model, which recapitulates many—but not all—features of human IPF.
• Cell-type specificity: The focus is on AECIIs; whether other epithelial or immune cell populations contribute to the observed lipid alterations remains to be clarified.
• Clinical translation: Although AAV-mediated gene delivery is effective in murine models, scalable and safe delivery approaches for human application need development.
• Receptor specificity: The precise receptor targets and downstream signaling pathways of LysoPCs in fibroblasts require further dissection for potential drug discovery.

Nonetheless, the robust demonstration of a causal link between HMGCS2 downregulation, LysoPC release, and fibroblast activation provides a valuable mechanistic framework for future smooth muscle contraction studies, lipid signaling pathway analysis, and inflammation mechanism research in fibrotic diseases.

Research Support Resources

To facilitate experimental exploration of lysophospholipid signaling in fibrosis and related contexts, researchers can utilize 1-myristoylglycerophosphocholine (SKU M1340), a characterized monoglycerophospholipid available from APExBIO. This compound is suitable for use in cell-based assays and physiological models to study lipid-mediated fibroblast activation, membrane dynamics, and antispasmodic effects, as demonstrated in the reference workflow. For optimal results, it is recommended to prepare fresh solutions according to the product guidelines and select solvent systems compatible with the intended assay format.